Collaborations are an essential part of Da Volterra’s strategy as they provide additional expertise and funding to advance the development of our products towards commercialization.

Da Volterra is willing to enter into a variety of partnership agreement focused on its research and discovery capabilities and pipeline. Many different types of cooperation schemes are possible: R&D consortium, academic cooperation, industrial co-development agreements or out-licensing deals.

Out / In-licensing

We intend to carry on building our pipeline and develop our portfolio in microbiome protection with the innovations that stem from our R&D teams.

We seek product licensing deals with pharmaceutical and biotechnology companies that would be interested in co-developing our products to tackle the gut microbiome dysbiosis consequences and improve health of patients worldwide.

Current partnerships

European Investment Bank (EIB)

In July 2017, Da Volterra signed a €20 million loan agreement with the European Investment Bank (EIB) to support the development of the DAV132 program.
The loan is part of the European innovation financing scheme InnovFin, an initiative launched by the EIB in cooperation with the European Commission under the European Union’s Horizon 2020 research and innovation program.

Da Volterra received the loan in two stages: a first tranche of €12 million in April 2018 and the second for €8 million in February 2021.


Da Volterra officially joined the COMBACTE-NET consortium in November 2016 and took the lead of Work Package 7. In 2020, Da Volterra became the leader for the whole consortium.

In COMBACTE-NET Work Package 7, Da Volterra and its partners are conducting 2 clinical studies:
– an observational study named ANTICIPATE (AssessmeNT of the Incidence of Clostridium difficile Infections in hospitalized Patients on Antibiotic Treatment) today completed
– an interventional phase 3 trial, named MICROCARE. MICROCARE is a multicenter, randomized, placebo-controlled, parallel-arm clinical trial to evaluate the efficacy of DAV132 in patients with newly-diagnosed Acute Myeloid Leukemia or high-risk Myelodysplastic Syndrome treated with intensive chemotherapy.

COMBACTE-NET receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement nr. 115620, resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies contribution.

Past partnerships


Da Volterra was a partner of the COMBACTE-CDI consortium which started in November 2017. The project aimed to develop a detailed understanding of the epidemiology and clinical impact of Clostridium difficile infection across Europe.

A large epidemiology study was undertaken across Europe to quantify the burden of CDI across the whole healthcare economy.

COMBACTE-CDI received support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement n° 777362 resources of which are composed of financial contribution from the European Union’s Horizon 2020 research and innovation programme, and EFPIA companies contribution.


BIOASTER and Da Volterra signed an agreement to initiate a research partnership based on the novel economic model of Technology Research Institute (TRIs).

The project, entitled DACCAR, (Destroy Antibiotics in Colon to Combat Antibiotic Resistance), aimed to develop an innovative product limiting the emergence of multi-resistant bacteria in patients treated with antibiotics to protect the intestinal microbiome from antibiotics side effects. Such a product would result in minimizing the nosocomial infections burden and maintaining effectiveness of antibiotics (noteworthy carbapenems) by reducing the spread of antibiotic resistance.


TRAIN-ASAP (Training and Research Aimed at Novel Antibacterial Solutions in Animals and People) was a Marie Curie Initial Training Network funded under the 7th Framework Program of the European Commission.

TRAIN-ASAP addressed the lack of effective antibacterial drugs againt resistant bacteria which poses a serious threat to human health and has a huge economical consequences to the healthcare system.

The project was dedicated to the scientific and professional training of 14 early-stage researchers with the aim to develop novel antibacterial solutions for humans and animals. The consortium included 9 academic institutions, 8 private enterprises and 2 national research centers representing 10 countries.